ジャーナル・オブ・オンコロジー・トランスレーショナル・リサーチ

Advances in ALK Targeted Therapy for Neuroblastoma

Abstract

Libo Zhang and Sylvain Baruchel

Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and prognostic alterations, to stratify the risk of recurrence or progression, and to develop optimal monitoring and treatment strategies in this malignancy.